- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Skye Bioscience Inc (SKYE)
Skye Bioscience Inc stock price live, this page displays NASDAQ SKYE stock exchange data. View the SKYE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Skye Bioscience Inc real time stock price chart below.
What Is the Skye Bioscience Inc Stock Price Today?
The Skye Bioscience Inc stock price today is 2.1700.
What Is the Stock Symbol for Skye Bioscience Inc?
The stock ticker symbol for Skye Bioscience Inc is SKYE.
Is SKYE the Same as $SKYE?
$SKYE is a common way to refer to the Skye Bioscience Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Skye Bioscience Inc Trade On?
Skye Bioscience Inc is listed and trades on the NASDAQ stock exchange.
Is Skye Bioscience Inc a Good Stock to Buy?
Determining whether Skye Bioscience Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Skye Bioscience Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SKYE quote. (ISIN: US83086J3095)
What Is the Skye Bioscience Inc Stock Price Today?
The Skye Bioscience Inc stock price today is 2.1700.
What Is the Stock Symbol for Skye Bioscience Inc?
The stock ticker symbol for Skye Bioscience Inc is SKYE.
Is SKYE the Same as $SKYE?
$SKYE is a common way to refer to the Skye Bioscience Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Skye Bioscience Inc Trade On?
Skye Bioscience Inc is listed and trades on the NASDAQ stock exchange.
Is Skye Bioscience Inc a Good Stock to Buy?
Determining whether Skye Bioscience Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Skye Bioscience Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SKYE quote. (ISIN: US83086J3095)
2.1700
0.0000(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.9700
2.3200
52 wk Range
1.9700
39.9216
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.97002.3200
52 wk Range
1.970039.9216
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SKYE Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
60.8000
Upside
+2,701.84%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
Skye Bioscience to acquire Redx Pharma in $125M deal- Investing.com
Form 8K Skye Bioscience Inc For: 19 August- Investing.com
- Form 8K Skye Bioscience Inc For: 14 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 60.8000
(+2,701.84% Upside)
Skye Bioscience Inc SWOT Analysis
Financial Outlook | Analyst price targets range from $14 to $15, with Skye's $59.2M cash position supporting operations through Q1 2027 despite current unprofitability |
Market Potential | With a growing obesity epidemic, Skye Bioscience targets a substantial market opportunity, competing against established players in the pharmaceutical industry |
Safety Edge | Nimacimab's peripherally restricted design aims to avoid neuropsychiatric side effects, a common issue with previous CB1 inhibitors |
Obesity Breakthrough | Skye Bioscience's nimacimab shows promise in preclinical trials, potentially revolutionizing weight management with its unique CB1 inhibitor mechanism |
Skye Bioscience Inc Earnings Call Summary for Q4/2025
- Skye Bioscience ended 2025 with $25.7M in cash, extending operational runway through Q4 2026 via disciplined capital allocation.
- CBeyond trial demonstrated significant weight loss when nimacimab combined with semaglutide, targeting second-line obesity treatment market.
- Company advancing Antibody-Peptide Conjugate program alongside CB1 antibody nimacimab to simplify dosing regimens for obesity therapy.
- Four analysts revised earnings upward; InvestingPro rates financial health 'GREAT' at 3.65 despite pre-revenue clinical-stage status.
- Key risks include FDA regulatory hurdles for combination therapies, funding constraints, and competition from established GLP-1 treatments.
Last Updated: 03/10/2026, 05:35 PM
Read Full TranscriptSkye Bioscience investor slides for Q4/2025
Last Update: Mar 10, 2026
See full investor slides
Earnings
Latest Release
Aug 14, 2026
EPS / Forecast
-2.16 / -1.98
Revenue / Forecast
-- / --
Compare SKYE to Peers and Sector
Metrics to compare | SKYE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSKYEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.2x | −1.2x | −0.4x | |
PEG Ratio | 0.01 | −0.08 | 0.00 | |
Price / Book | −19.3x | 3.3x | 2.6x | |
Price / LTM Sales | - | 190.7x | 3.1x | |
Upside (Analyst Target) | - | 625.2% | 49.3% | |
Fair Value Upside | Unlock | −2.7% | 6.7% | Unlock |
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Skye Bioscience (SKYE) Stock Price Today?
The Skye Bioscience stock price today is 2.1700 USD.
What Stock Exchange Does Skye Bioscience Trade On?
Skye Bioscience is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Skye Bioscience?
The stock symbol for Skye Bioscience is "SKYE."
What Is the Skye Bioscience Market Cap?
As of today, Skye Bioscience market cap is 60.9000M USD.
What Is Skye Bioscience's Earnings Per Share (TTM)?
The Skye Bioscience EPS (TTM) is -10.2399.
When Is the Next Skye Bioscience Earnings Date?
Skye Bioscience will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is SKYE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Skye Bioscience Stock Split?
Skye Bioscience has split 3 times.
What is the current trading status of Skye Bioscience (SKYE)?
As of Aug 26, 2026, Skye Bioscience (SKYE) is trading at a price of 2.1700 USD, with a previous close of 2.5500 USD. The stock has fluctuated within a day range of 1.9700 USD to 2.3200 USD, while its 52-week range spans from 1.9700 USD to 39.9216 USD.
What Is Skye Bioscience (SKYE) Price Target According to Analysts?
The average 12-month price target for Skye Bioscience is 60.8000 USD, with a high estimate of 160 USD and a low estimate of 16 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +2,701.84% Upside potential.
What Is the SKYE After Hours Price?
SKYE's last after hours stock price is 2.1900 USD, the stock has decreased by 0.0200, or 0.9200%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.